About Acuamark Diagnostics
Acuamark Diagnostics is a private company based in New York, New York. It has reported $20,333,197 raised in four offerings on Form D since November 2016. Its chief executive is Bernard Peperstraete.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 22, 2024 | Jun 4, 2024 | $4,941,620of $11.9M target | 20 | $247K | Equity, OptionsRule 506(b) | Form D ↗ |
| Mar 21, 2022 | Apr 6, 2022 | $11,623,242of $13.6M target | 41 | $283K | EquityRule 506(b) | Form D ↗ |
| Sep 10, 2019 | Sep 25, 2019 | $2,289,501of $5.3M target | 29 | $78,948 | EquityRule 506(b) | Form D ↗ |
| Sep 1, 2016 | Nov 17, 2016 | $1,478,834of $1.7M target | 20 | $73,942 | Equity, Options, Securities on exercise, Series A1 Preferred Stock convertible into Common StockRule 506(b) | Form D ↗ |
| Total, four offerings | $20,333,197 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Acuamark Diagnostics's Form D filed Jun 4, 2024.
Earlier filings also listed Michael Gargano (director, last listed Sep 2019), Joseph Smith (director, last listed Sep 2019), Howard Johnson (director, last listed Sep 2019), Gregory Murdock (director, last listed Sep 2019), Michael Hanbury (director, last listed Nov 2016), David Weavil (director, last listed Nov 2016) and Brian Carr (director, last listed Nov 2016).